Skip to main content
. 2019 Nov 19;10(62):6668–6677. doi: 10.18632/oncotarget.27313

Figure 2. Tumor growth restriction of Cav1Y14D MDA-MB-435 cells.

Figure 2

(A) Tumor growth of the MDA-MB-435 Cav1 Y14 stables following s.c. injection in nude mice was monitored; tumor size, latency and log phase growth are presented. (B) MDA-MB-435 tumors were labeled with H&E and immunostained for TP53. (C) Mean intensity of TP53 labeling in tumors was quantified (** p < 0.01; ANOVA, Scale bar: 50 μm).